Anbio Biotechnology’s NNNN share price has surged by 5.23%, which has investors questioning if this is right time to sell.

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic CollaborationBRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro ...

Anbio Biotechnology (NNNN), a developer of in vitro diagnostics, has filed to raise around $9M through a U.S. initial public offering. The medtech company said in an SEC filing that it was looking ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Overview: Anbio Biotechnology is a company that specializes in providing in vitro diagnostics (IVD) products across various regions, including the European Union, Asia Pacific, North America ...

We've identified the following companies as similar to Anbio Biotechnology because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to ...

In this dynamic environment, identifying small-cap stocks like Anbio Biotechnology that possess strong growth potential and innovative capabilities can offer intriguing opportunities for investors ...

IPO Roundup: Advanced Biomed, Brag House Holdings and more IPO Roundup: Anbio Biotechnology, Wellgistics Health and more Financial information for Basel Medical Group Ltd Seeking Alpha’s Quant ...

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...